; (2) from the list under paragraph (1), identify a first drug to be transferred; (3) determine the criteria necessary to receive approval of the supplemental application; and (4) require the applicant to demonstrate, as part of such criteria, that each foreign establishment from which the drugs are to be transferred has a satisfactory inspection history with respect to the drugs. (d) Subsequent transfer of drugs that share a similar manufacturing process After the approval of a supplemental application under subsection (a) for the transfer of the manufacturing of a first drug identified by the Secretary pursuant to subsection (c)(2) from one or more foreign establishments to one or more new or existing domestic establishments, the Secretary may allow the applicant to so transfer drugs that share a similar manufacturing process with such first drug pursuant to submission of a report under section 506A(d)(2) rather than by requiring submission of a supplemental application. (e) Working group (1) Establishment Not later than 90 days after the date of enactment of this section, the Secretary shall establish an intra-agency working group to be known as the Facility Transfer Working Group. (2) Membership The Secretary shall appoint members of the Facility Transfer Working Group from among officials and employees of the Department of Health and Human Services who— (A) represent a cross-section of the Department of Health and Human Services; and (B) have expertise on establishments used to manufacture drugs. (3) Duties The Facility Transfer Working Group shall— (A) assist the Secretary in carrying out this section; (B) upon request by an applicant, conduct an informational site visit during the developmental phase to discuss requirements with the applicant with respect to facility design, site status, and validation